Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Corlaner

This page shows the latest Corlaner news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.

Latest news

  • Amgen starts shipping Corlaner in US Amgen starts shipping Corlaner in US

    Firm also reports healthy financial growth in the first quarter.  . Amgen has started shipping its Corlaner heart failure therapy to wholesalers in the US just a few days after getting FDA ... Corlaner (ivabradine) - the first new medicine for chronic

  • FDA clears Amgen's Corlaner for heart failure FDA clears Amgen's Corlaner for heart failure

    The FDA approved Corlaner (ivabradine) after a priority review for reducing the risk of hospitalisation for worsening heart failure in patients with stable, symptomatic chronic heart failure (CHF). . ... Corlaner's approval is based on the results of

  • Amgen banking on three launches in 2015 Amgen banking on three launches in 2015

    year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma. ... Despite the upbeat comments, Amgen did reveal that Corlaner and T-VEC have both been delayed by requests for

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Corlaner costs around the same as Entresto at around $4, 500 per year. ... Entresto and Corlaner are expected to account for the bulk of that increase, with Entresto taking the lion's share.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...

Quick links